Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Andrew Grube"'
Autor:
Michael Doherty, Ke Xu, Tong Zi, Sriram Sathyanaryanan, Nuruddeen Lewis, Chang Ling Sia, Katherine Kirwin, Sonya Haupt, Gauri Mahimkar, Kevin Dooley, Su Chul Jang, Bryan Choi, Andrew Grube, Christine McCoy, Jorge Sanchez-Salazar, Scott Estes, Kyriakos Economides, Douglas Williams
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/7d43f8f3245a4665b0ac30f60b09a115
Autor:
Sriram Sathyanarayanan, Douglas E. Williams, Kyriakos D. Economides, Scott Estes, Leonid Gaidukov, Michael Doherty, Jorge Sanchez-Salazar, Christine McCoy, Andrew Grube, Adam Boutin, Bryan Choi, Su Chul Jang, Kevin Dooley, Ke Xu, Tong Zi, Gauri Mahimkar, Sonya Haupt, Katherine Kirwin, Chang Ling Sia, Nuruddeen D. Lewis
Reagents and antibodies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c0cc52ff5f90d222f6c91fd94d9fb5d
https://doi.org/10.1158/1535-7163.22520857.v1
https://doi.org/10.1158/1535-7163.22520857.v1
Autor:
Sriram Sathyanarayanan, Douglas E. Williams, Kyriakos D. Economides, Scott Estes, Leonid Gaidukov, Michael Doherty, Jorge Sanchez-Salazar, Christine McCoy, Andrew Grube, Adam Boutin, Bryan Choi, Su Chul Jang, Kevin Dooley, Ke Xu, Tong Zi, Gauri Mahimkar, Sonya Haupt, Katherine Kirwin, Chang Ling Sia, Nuruddeen D. Lewis
The promise of IL12 as a cancer treatment has yet to be fulfilled with multiple tested approaches being limited by unwanted systemic exposure and unpredictable pharmacology. To address these limitations, we generated exoIL12, a novel, engineered exos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b48f064854755ca4ed6549b6b5758945
https://doi.org/10.1158/1535-7163.c.6542815.v1
https://doi.org/10.1158/1535-7163.c.6542815.v1
Autor:
Sriram Sathyanarayanan, Douglas E. Williams, Kyriakos D. Economides, Scott Estes, Leonid Gaidukov, Michael Doherty, Jorge Sanchez-Salazar, Christine McCoy, Andrew Grube, Adam Boutin, Bryan Choi, Su Chul Jang, Kevin Dooley, Ke Xu, Tong Zi, Gauri Mahimkar, Sonya Haupt, Katherine Kirwin, Chang Ling Sia, Nuruddeen D. Lewis
Mean Cytokine Values in Cynomolgus Plasma After Subcutaneous Dosing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b72abef236439adc462be2e495a07859
https://doi.org/10.1158/1535-7163.22520860.v1
https://doi.org/10.1158/1535-7163.22520860.v1
Autor:
Sriram Sathyanarayanan, Douglas E. Williams, Kyriakos D. Economides, Scott Estes, Leonid Gaidukov, Michael Doherty, Jorge Sanchez-Salazar, Christine McCoy, Andrew Grube, Adam Boutin, Bryan Choi, Su Chul Jang, Kevin Dooley, Ke Xu, Tong Zi, Gauri Mahimkar, Sonya Haupt, Katherine Kirwin, Chang Ling Sia, Nuruddeen D. Lewis
Fold-change Cytokine Values in Cynomolgus Plasma After Subcutaneous Dosing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::565f93cee3c4ea09b46e8867aafda435
https://doi.org/10.1158/1535-7163.22520869.v1
https://doi.org/10.1158/1535-7163.22520869.v1
Autor:
Sriram Sathyanarayanan, Douglas E. Williams, Kyriakos D. Economides, Scott Estes, Leonid Gaidukov, Michael Doherty, Jorge Sanchez-Salazar, Christine McCoy, Andrew Grube, Adam Boutin, Bryan Choi, Su Chul Jang, Kevin Dooley, Ke Xu, Tong Zi, Gauri Mahimkar, Sonya Haupt, Katherine Kirwin, Chang Ling Sia, Nuruddeen D. Lewis
Figures S1 through S6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41c5b51e812ca6bddaccbe1b538f459a
https://doi.org/10.1158/1535-7163.22520863
https://doi.org/10.1158/1535-7163.22520863
Autor:
Sriram Sathyanarayanan, Douglas E. Williams, Kyriakos D. Economides, Scott Estes, Leonid Gaidukov, Michael Doherty, Jorge Sanchez-Salazar, Christine McCoy, Andrew Grube, Adam Boutin, Bryan Choi, Su Chul Jang, Kevin Dooley, Ke Xu, Tong Zi, Gauri Mahimkar, Sonya Haupt, Katherine Kirwin, Chang Ling Sia, Nuruddeen D. Lewis
20201229pdtedSupplementaryFigures.pdf from Exosome Surface Display of IL12 Results in Tumor-Retained Pharmacology with Superior Potency and Limited Systemic Exposure Compared with Recombinant IL12
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::187f061226a25f50c15b215a72a23107
https://doi.org/10.1158/1535-7163.22520872.v1
https://doi.org/10.1158/1535-7163.22520872.v1
Autor:
Bryan D. Choi, Su Chul Jang, Tong Zi, Christine McCoy, Gauri Mahimkar, Sonya Haupt, Williams Douglas E, Katherine Kirwin, Ke Xu, Michael Doherty, Kyriakos D. Economides, Sriram Sathyanaryanan, Jorge Sanchez-Salazar, Andrew Grube, Scott Estes, Chang Ling Sia, Nuruddeen D. Lewis, Kevin Dooley
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background The promise of Interleukin-12 as a cancer treatment has yet to be fulfilled with multiple tested approaches being limited by unwanted systemic exposure and unpredictable pharmacology. To address these limitations, we generated exoIL-12™,
Autor:
Gauri Mahimkar, Scott Estes, Kyriakos D. Economides, Chang Ling Sia, Su Chul Jang, Jorge Sanchez-Salazar, Andrew Grube, Christine McCoy, Kevin Dooley, Nuruddeen D. Lewis, Sriram Sathyanarayanan, Sonya Haupt, Ke Xu, Tong Zi, Bryan D. Choi, Leonid Gaidukov, Williams Douglas E, Michael Doherty, Adam T. Boutin, Katherine Kirwin
Publikováno v:
Molecular cancer therapeutics. 20(3)
The promise of IL12 as a cancer treatment has yet to be fulfilled with multiple tested approaches being limited by unwanted systemic exposure and unpredictable pharmacology. To address these limitations, we generated exoIL12, a novel, engineered exos